NeuroSolutions Enters into a Collaboration Agreement with Gentronix
News Jun 08, 2006
Pursuant to the agreement both companies will seek to assess the genetic toxicology of NSL-105 by using GreenScreen, Gentronix’s commercially available yeast-based assay.
In particular, the assay’s specificity is demonstrated by the extremely low incidence of false positives compared to other available tests.
NeuroDiscovery Chairman, Dr Mark Treherne said, "We are delighted to collaborate with Gentronix and this agreement will provide us with a significant opportunity to accelerate the development of NSL-105 to build an in-depth pipeline of innovative products for the treatment of a variety of painful medical conditions."
"Recent forecasts predict a global market value for neuropathic pain treatments of over US$4 billion by 2007."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019